Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery
Open Access
- 14 November 2021
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 97 (2) , E51-E54
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Sutimlimab in Cold Agglutinin DiseaseNew England Journal of Medicine, 2021
- Cold agglutinin disease revisited: a multinational, observational study of 232 patientsBlood, 2020
- Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal StudyBlood, 2019
- Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin DiseaseSeminars in Hematology, 2018
- Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trialBlood, 2017
- Prophylactic use of eculizumab during surgery in chronic cold agglutinin diseaseBMJ Case Reports, 2017
- Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypassThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Acute Phase Haemolysis in Chronic Cold Agglutinin DiseaseScandinavian Journal of Immunology, 2001
- Clinical immunology of chronic cold agglutinin diseaseEuropean Journal of Haematology, 1999